Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: The Contribution of Glucagon-like Peptide-1

Journal of Cardiovascular Pharmacology

Volumn 66, Issue 2, 2015, Pages 159-164

  Moroi, Masao ^a   Kubota, Tetsuya ^b  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b Institute of Physical and Chemical Research   (Japan)

Author keywords

Diuresis; exendin9 39; GLP 1 receptor agonist; GLP 1 receptor antagonist; Na+ H+ exchanger; natriuresis

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; POTASSIUM; SODIUM; TENELIGLIPTIN; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; GLUCOSE BLOOD LEVEL; NATRIURETIC FACTOR; PYRAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIURETIC ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; LIMIT OF DETECTION; MALE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION; URINE VOLUME; ANIMAL; BLOOD; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DIURETICS; GLUCAGON-LIKE PEPTIDE 1; MALE; NATRIURESIS; NATRIURETIC AGENTS; PYRAZOLES; RATS; RATS, WISTAR; THIAZOLIDINES;

EID: 84939647002     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000258     Document Type: Article

References (25)

1. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153-165.
2. Kieffer TJ, Mcintosh CH, Pederson RA. Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585-3596.
3. Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209-294.
4. Pørksen N, Munn S, Steers J, et al. Effects of glucose ingestion versus infusion on pulsatile insulin secretion. The incretin effect is achieved by amplification of insulin secretory burst mass. Diabetes. 1996;45:1317-1323.
5. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157.
6. Abu-Hamdah R, Rabiee A, Meneilly GS, et al. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94:1843-1852.
7. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney Blood Press Res. 2012;36:65-84.
8. Yoon JS, Lee HW. Understanding the cardiovascular effects of incretin. Diabetes Metab J. 2011;35:437-443.
9. von Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens. 2014;23:54-60.
10. Rieg T, Gerasimova M, Murray F, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Ren Physiol. 2012;303:F963-F971.
11. Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Ren Physiol. 2011;301:F355-F363.
12. Gutzwiller JP, Hruz P, Huber AR, et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006;73:142-150.
13. Schlatter P, Beglinger C, Drewe J, et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007; 141:120-128.
14. Gonzalez-Gronow M, Misra UK, Gawdi G, et al. Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells. J Biol Chem. 2005;280:27173-27178.
15. Girardi AC, Knauf F, Demuth HU, et al. Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol. 2004;287:C1238-C1245.
16. Fukuda-Tsuru S, Anabuki J, Abe Y, et al. A novel, potent, and longlasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012;696:194-202.
17. Nakagami H, Pang Z, Shimosato T, et al. The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertens Res. 2014;37:629-635.
18. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567-575.
19. Shirasaki Y, Ito Y, Kikuchi M, et al. Validation studies on blood collection from the jugular vein of conscious mice. J Am Assoc Lab Anim Sci. 2012;51:345-351.
20. Girardi AC, Degray BC, Nagy T, et al. Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem. 2001;276:46671-46677.
21. Mason RP, Jacob RF, Kubant R, et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb. 2011;18:774-783.
22. Ishii M, Shibata R, Kondo K, et al. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric oxide synthase-dependent mechanism. J Biol Chem. 2014;289:27235-27245.
23. Shih CM, Chen YH, Lin YW, et al. MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression. Curr Med Chem. 2014;21:2012-2022.
24. Brandt I, Lambeir AM, Ketelslegers JM, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006;52:82-87.
25. Gomez N, Touihri K, Matheeussen V, et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14:14-21.